*仅供医学专科东说念主士阅读参考

随从“医学界”的脚步，速来一探究竟！

撰文 |小驰

2023年9月9日-12日，领域行家畛域最大的学术会议之一的天下肺癌大会（WCLC）行将在新加坡深广开幕。日前,官网已公布了纲目标题。在晚期NSCLC领域，免疫调整与靶向调整的谈论谈判百花皆放，涵盖了调整靶点与生物标记物的设立、新药的早期临床检会、大型谈判的永久随访终了、探索不同药物的蚁集调整形式等方方面面，为不雅众呈现了靶免期间晚期肺癌谈判发达的全景图。

OA09.Immunotherapy for Advanced NSCLC

晚期NSCLC免疫调整

▌OA09.03

STK11/LKB1 Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy in NSCLC: Results From Three Randomized Trials

STK11/LKB1弱势表型而非突变能裁汰NSCLC免疫调整效用：三项立地检会的终了

讲者：A.Li | Sun Yat-sen University Cancer Center, Guangzhou/CN

▌OA09.04

ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors

ILLUMINATE谈判：度伐利尤单抗-Tremelimumab蚁集化疗用于EGFR扼制剂调整后出现发达的EGFR突变型NSCLC调整的疗效与安全性

讲者：C.Lee | University of Sydney, Sydney/AU

▌OA09.05

A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004)

斯鲁利单抗蚁集化疗用于鳞癌一线调整的三期谈判（ASTRUM-004）

讲者：周彩存教诲，上海市肺科病院

▌OA09.06

IMpower151: Phase Ⅲ Study of Atezolizumab + Bevacizumab + Chemotherapy in 1L Metastatic Nonsquamous NSCLC

IMpower151谈判：阿替利珠单抗+贝伐珠单抗+化疗用于升沉性非鳞状NSCLC一线调整的Ⅲ期临床谈判

讲者：周彩存教诲，上海市肺科病院

OA14.Immune Checkpoint Therapy: Long Term Follow Up

免疫查验点扼制剂：永久随访

▌OA14.03

Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227

纳武利尤单抗+伊匹木单抗用于升沉性NSCLC的6年糊口及健康谈论生活质料终了：CheckMate227谈判

讲者：S.S. Ramalingam | Winship Cancer Institute, Emory University, Atlanta/GA/USA

▌OA14.04

Three-Year Outcomes with First-Line Pembrolizumab, in Patients with Non-Small-Cell Lung Cancer and A PD-L1 Tumor Proportion Score >90%

帕博利珠单抗一线调整PD-1肿瘤细胞阳性比例分数＞90％的一线调整NSCLC的3年终了

讲者：B.Ricciuti | Dana-Farber Cancer Institute, Boston/MA/USA

▌OA14.05

5-Year Survival of Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%

帕博利珠单抗蚁集化疗用于PD-L1肿瘤细胞阳性比例分数＜1％的升沉性NSCLC的5年糊口终了

讲者：S.Gadgeel | Department of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Health, Detroit/MI/USA

▌OA14.06R

Reported Cardiovascular Events in Lung Cancer Patients after Immune-Checkpoint Inhibitor Therapy

肺癌患者接纳免疫查验点扼制剂调整后的心血行状件论述

讲者：S-C. Yeung | MD Anderson Cancer Center, Houston/TX/USA

MA15.Bringing New Discoveries into Early Phase Clinical Trials

早期临床检会的新发现

▌MA15.03

Harnessing Cornification and Tumor Microenvironment for Evaluation of Immunotherapy Efficacy in Squamous Cell Lung Carcinoma

愚弄角化现象与肿瘤微环境评估免疫疗法调整鳞状细胞肺癌的效用

讲者：M.Jiang | Shanghai Pulmonary Hospital, Shanghai/CN

▌MA15.04

Timing of Pre-Biopsy COVID-mRNA Vaccination and PD-L1 Expression in Advanced Non-Small Cell Lung Cancer

晚期NSCLC患者活检前接种COVID-mRNA疫苗的时机与PD-L1的抒发

讲者：A. Grippin | The University of Texas MD Anderson Cancer Center, Houston/TX/USA

▌MA15.06

Association of Pathomics-based MHC-II Assessment with NSCLC Immunotherapy Efficacy

基于病理组学的MHC-II评估与NSCLC免疫调整疗效的谈论性

讲者：J.Liu | Sun Yat-sen University Cancer Center, Guangzhou/CN

▌MA15.08

Multicenter Phase II Trial of LN-145 TIL Cell Therapy plus Pembrolizumab in Patients with ICI-Naïve Metastatic NSCLC

LN-145 TIL细胞调整蚁集帕博利珠单抗调整免疫查验点扼制剂初治的升沉性NSCLC患者的多中心Ⅱ期检会

讲者：A.J. Schoenfeld | Memorial Sloan Kettering Cancer Center, New York/NY/USA

▌MA15.09A

Phase I/II Study of TQ-B2450 plus Anlotinib in EGFR+ Advanced NSCLC Patients Failed to Prior EGFR TKI Therapies:Phase II Results Updates

TQ-B2450蚁集安罗替尼用于过往EGFR TKI调整失败的EGFR阳性晚期NSCLC患者的Ⅰ/Ⅱ期谈判：Ⅱ期终了更新

讲者：史好意思祺，江苏省肿瘤病院

▌MA15.10

Ph 2 Trial of IO102-IO103 Vaccine Plus Pembrolizumab: Preliminary Results for the First-line Treatment of Lung Adenocarcinoma

IO102-IO103疫苗蚁集帕博利珠单抗的2期检会：肺腺癌一线调整终了

讲者：J.W. Riess | UC Davis Comprehensive Cancer Center, Sacramento/CA/USA

▌MA15.11

Phase II Study of Nivolumab Plus Ipilimumab with Chemotherapy for Advanced NSCLC with Untreated Brain Metastases: NIke Trial (LOGiK2004)

纳武利尤单抗蚁集伊匹木单抗+化疗用于伴有未经调整的脑升沉的晚期NSCLC调整的Ⅱ期谈判（LOGiK2004）

讲者：Y.Tsuchiya-Kawano | Kitakyushu Municipal Medical Center, Kitakyushu/JP

OA03. Newer Generation Treatments for EGFR, ALK and ROS4

靶向EGFR、ALK、ROS4的新一代调整

▌OA03.03

Aumolertinib Plus Anlotinib in Advanced NSCLC with Brain Metastasis: A Single-arm, Phase II Study

阿好意思替尼蚁集安罗替尼用于伴脑升沉的晚期NSCLC调整：一项单臂、Ⅱ期谈判

讲者：陈丽昆，中山大学附庸肿瘤病院

长风推球：昨日预测再红一场瑞典超，命中哈马比主场赢球，收获一波10连红，长线战绩近22中21，周六解析欧冠决赛，还有早场稳胆，值得继续关注！[查看今日推荐]

苏明快乐8第2023151期9次012路分析

▌OA03.04

A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions

一项伏好意思替尼（一种口服、具有脑浸透性的聘任性EGFR扼制剂）用于EGFR exon 20 ins突变NSCLC调整的Ⅰb期谈判

讲者：Y. Shi | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing/CN

▌OA03.06

Repotrectinib in Patients with ROS1 Fusion-positive (ROS1+) NSCLC: Update from the Pivotal Phase 1/2 TRIDENT-1 Trial

Repotrectinib 调整ROS1和会阳性NSCLC患者：要道性1/2期谈判TRIDENT-1检会的最新发达

讲者：B.C. Cho | Yonsei Cancer Center, Yonsei University College of Medicine, Seoul/KR

▌OA21.03

A Phase 3b Study of 1L Savolitinib in Patients with Locally Advanced or Metastatic NSCLC Harboring MET Exon 14 Mutation

赛沃替尼用于伴MET exon 14突变的局部晚期或升沉性NSCLC的3b期谈判

讲者：陆舜，附庸胸科病院

▌OA21.04

Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study

Amivantamab用于调整具有MET 14番外显子逾越突变的晚期NSCLC患者：来自CHRYSALIS谈判的终了

讲者：N. Leighl | Princess Margaret Cancer Centre, Toronto/ON/CA

▌OA21.05

Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis

Tepotinib蚁集奥希替尼用于一线使用奥希替尼调整后归并MET扩增的EGFR突变NSCLC：INSIGHT 2谈判初步分析

讲者：T.M. Kim | Seoul National University Cancer Research Institute, Seoul/KR

▌OA21.06

ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial

在VISION检会中，经Tepotinib调整MET 14番外显子逾越突变的NSCLC患者的ctDNA能源学、预后标记物和耐药性机制

讲者：X.Le | Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston/TX/USA

MA06. Targeted Therapy: KRAS and Beyond

靶向疗法：KRAS过甚他

▌MA06.03

KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

KontRASt-01：JDQ443+TNO155用于晚期KRAS G12C突变实体瘤调整的初步安全性和有用性

讲者：M.V. Negrao | MD Anderson Cancer Center, Houston/TX/USA

▌MA06.04

KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRAS G12C-Mutated NSCLC

KRYSTAL-1：Adagrasib (MRTX849) 单药调整KRAS G12C突变晚期NSCLC的2年随访终了

讲者：S.Gadgeel | Henry Ford Cancer Institute, Henry Ford Health System, Detroit/MI/USA

▌MA06.05

CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC.

CodeBreaK 101：Sotorasib蚁集卡铂+Pemetrexed 蚁集调整伴KRAS G12C突变的晚期NSCLC的安全性和有用性

讲者：J.M. Clarke | Duke Cancer Institute, Durham/NC/USA

▌MA06.06A

Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J

Ceralasertib蚁集度伐利尤单抗用于归并或辞别并RAS突变的晚期NSCLC调整的Ⅱ期检会：NLMT J臂的终了

讲者：G. Middleton | University of Birmingham, Birmingham/GB

▌MA06.08

Real-World Landscape Analysis of Activating ERBB2/ERBB3 Alterations in 107,561 Tissue and Plasma Samples from Patients with NSCLC

107561例NSCLC患者组织和血浆样本中活化ERBB2/ERBB3突变的信得过天下景不雅分析

讲者：D. Liu | Memorial Sloan Kettering Cancer Center, New York City/NY/USA

▌MA06.10

Discovery of Potent Degraders of KRASG12D Based on a Novel KRAS Binder

基于新式KRAS binder的高效KRASG12D降解剂的研发

讲者：陆舜，上海交通大学附庸胸科病院

MA13. Targeted Therapy: EGFR and Her2

靶向疗法：EGFR与HER2

▌MA13.03

BBT-176, a 4th Generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: Updated Report from a Phase 1 Study

BBT-176，一种第4代EGFR-TKI，用于EGFR-TKI调整后发达的NSCLC：1期谈判的最新论述

讲者：S.M. Lim | Yonsei Cancer Center, Seoul/KR

▌MA13.04

Final Overall Survival Analysis of Osimertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations (KCSG-LU15-09)

奥希替尼用于调整具有生分EGFR突变的NSCLC患者的最终糊口糊口终了分析（KCSG-LU15-09）

讲者：J.H. Cho | Incheon St.Mary's hospital, Incheon/KR

皇冠体育hg86a

▌MA13.05

Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study

阿好意思替尼蚁集埃克替尼用于伴核心神经系统突变的EGFR突变NSCLC一线调整：一项前瞻性Ⅰ/Ⅱ期谈判

讲者：黄媚娟，四川大学华西病院

▌MA13.06

Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2

阿好意思替尼、Lazertinib蚁集铂类药物为基础的化疗用于调整EGFR突变的晚期NSCLC：来自 CHRYSALIS-2的更新终了

讲者：S-H. Lee | Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul/KR

▌MA13.08

Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations

Beamion Lung 1，一项 HER2 TKI（BI 181063）调整HER2卓绝的晚期实体瘤患者的Ⅰa/Ⅰb期检会

讲者：N. Yamamoto |National Cancer Center Hospital, Tokyo/JP

▌MA13.09

Efficacy and Safety of Poziotinib in HER2 Exon 20 Insertion NSCLC Patients who Received at Least 2 Previous Systemic Therapies

Poziotinib用于既往曾接纳至少2种系统疗法的HER2 exon 20 ins突变NSCLC患者调整的疗效与安全性

讲者：X. Le | MD Anderson Cancer Center, Houston/TX/USA

▌MA13.10

Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02

德曲妥珠单抗用于HER2突变升沉性NSCLC患者调整：DESTINY-Lung02谈判的初步终了

讲者：P. Janne | Dana-Farber Cancer Institute, Boston/MA/USA

▌MA13.11

Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial

Lazertinib用于具有生分EGFR突变的NSCLC患者：一项单臂、Ⅱ期多中心检会

讲者：S. Park | Samsung Medical Center, Seoul/KR

精彩资讯等你来

背负剪辑：Sheep

*医学界致力其发表践诺专科、可靠，但不对践诺的准确性作念出开心；请谈论各方在接纳或以此行为方案依据时另行核查。